Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays

Authors: Philippe Halfon, Maria Teresa Sandri, Audrey Raimondo, Sophie Ravet, Hacène Khiri, Mario Sideri, Guillaume Penaranda, Claire Camus, Maria Luisa Mateos Lindemann

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Cervical cancer is caused by high-risk types of human papillomavirus (HPV). DNA testing of such high-risk types of HPV could improve cervical screening.The aim of the study was to compare the sensitivities and positive predictive values of two commercially available typing assays (Qiagen LQ and Roche LA) and to comparatively assess the distribution of HPV types with these two assays.

Methods

The study population comprised 311 ASCUS + women with abnormal pap tests who were HCII positive and who were admitted to three European referral gynecology clinics between 2007 and 2010 (Madrid, Marseille and Milan). All patients underwent LQ and LA tests.

Results

The sensitivity of the two assays for HPV typing was 94% for LQ and 99% for LA (compared with HCII). The overall concordance between LQ and LA was 93%. The three prevalent genotypes, HPV16, HPV18, and HPV31, were identified with a high concordance using the two assays: kappa 0.93, 0.83, and 0.91, respectively. Mixed genotypes were more frequently detected by LA than by LQ: 52% vs. 18%, respectively (p < .0001).

Conclusions

These assays have a good clinical sensitivity for detecting HPV types in CIN2+ patients and allow the virus type to be detected in the same experiment. Our study revealed no significant difference between LQ and LA for CIN2+ or CIN3+ diagnosis, indicating similar distributions of HPV types and a mixed genotype detection that is higher for LA than for LQ.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003, 95 (1): 46-52. 10.1093/jnci/95.1.46.CrossRefPubMed Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003, 95 (1): 46-52. 10.1093/jnci/95.1.46.CrossRefPubMed
2.
go back to reference Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008, 26 (Suppl 10): K29-K41.CrossRefPubMed Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008, 26 (Suppl 10): K29-K41.CrossRefPubMed
3.
go back to reference Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348 (6): 518-527. 10.1056/NEJMoa021641.CrossRefPubMed Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348 (6): 518-527. 10.1056/NEJMoa021641.CrossRefPubMed
4.
go back to reference Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005, 97 (14): 1072-1079. 10.1093/jnci/dji187.CrossRefPubMed Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005, 97 (14): 1072-1079. 10.1093/jnci/dji187.CrossRefPubMed
5.
go back to reference Woodman CB, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007, 7 (1): 11-22. 10.1038/nrc2050.CrossRefPubMed Woodman CB, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007, 7 (1): 11-22. 10.1038/nrc2050.CrossRefPubMed
6.
go back to reference zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002, 2 (5): 342-350. 10.1038/nrc798.CrossRefPubMed zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002, 2 (5): 342-350. 10.1038/nrc798.CrossRefPubMed
7.
go back to reference Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007, 197 (4): 346-355. 10.1016/j.ajog.2007.07.047.CrossRefPubMed Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007, 197 (4): 346-355. 10.1016/j.ajog.2007.07.047.CrossRefPubMed
8.
go back to reference Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L, Syrjanen K: Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis. 2008, 35 (5): 521-527. 10.1097/OLQ.0b013e318164e567.CrossRefPubMed Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L, Syrjanen K: Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis. 2008, 35 (5): 521-527. 10.1097/OLQ.0b013e318164e567.CrossRefPubMed
9.
go back to reference Halfon P, Benmoura D, Khiri H, Penaranda G, Blanc B, Riggio D, Sandri MT: Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. J Clin Virol. 2010, 47 (1): 38-42. 10.1016/j.jcv.2009.10.013.CrossRefPubMed Halfon P, Benmoura D, Khiri H, Penaranda G, Blanc B, Riggio D, Sandri MT: Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. J Clin Virol. 2010, 47 (1): 38-42. 10.1016/j.jcv.2009.10.013.CrossRefPubMed
10.
go back to reference Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B: Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ((R)) HPV assay. J Clin Virol. 2010, 47 (2): 177-181. 10.1016/j.jcv.2009.11.011.CrossRefPubMed Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B: Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ((R)) HPV assay. J Clin Virol. 2010, 47 (2): 177-181. 10.1016/j.jcv.2009.11.011.CrossRefPubMed
11.
go back to reference Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc B: Evaluation of the clinical performance of the Abbott RealTime high-risk HPV for carcinogenic HPV detection. J Clin Virol. 2010, 48 (4): 246-250. 10.1016/j.jcv.2010.05.008.CrossRefPubMed Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc B: Evaluation of the clinical performance of the Abbott RealTime high-risk HPV for carcinogenic HPV detection. J Clin Virol. 2010, 48 (4): 246-250. 10.1016/j.jcv.2010.05.008.CrossRefPubMed
12.
go back to reference Stoler MH, Wright TC, Sharma A, Apple R, Gutekunst K, Wright TL: High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011, 135 (3): 468-475. 10.1309/AJCPZ5JY6FCVNMOT.CrossRefPubMed Stoler MH, Wright TC, Sharma A, Apple R, Gutekunst K, Wright TL: High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011, 135 (3): 468-475. 10.1309/AJCPZ5JY6FCVNMOT.CrossRefPubMed
13.
go back to reference Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, et al: Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008, 17 (11): 3033-3042. 10.1158/1055-9965.EPI-08-0508.CrossRefPubMed Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, et al: Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008, 17 (11): 3033-3042. 10.1158/1055-9965.EPI-08-0508.CrossRefPubMed
14.
go back to reference Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc B: Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomark. 2010, 7 (3): 133-139.PubMed Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc B: Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomark. 2010, 7 (3): 133-139.PubMed
15.
go back to reference Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer CJ, van Doorn LJ, Quint WG: High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6 + −PCR and xMAP technology. J Clin Virol. 2009, 46 (Suppl 3): S21-S26.CrossRefPubMed Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer CJ, van Doorn LJ, Quint WG: High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6 + −PCR and xMAP technology. J Clin Virol. 2009, 46 (Suppl 3): S21-S26.CrossRefPubMed
16.
go back to reference Godinez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, Bravo IG, Bosch FX, de Sanjose S: Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infect Agent Cancer. 2011, 6: 23-10.1186/1750-9378-6-23.CrossRefPubMedPubMedCentral Godinez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, Bravo IG, Bosch FX, de Sanjose S: Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infect Agent Cancer. 2011, 6: 23-10.1186/1750-9378-6-23.CrossRefPubMedPubMedCentral
17.
go back to reference Halfon P, Lindemann ML, Raimondo A, Ravet S, Camus C, Khiri H, Penaranda G, Sideri M, Sandri MT: HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test. Arch Virol. 2013, 158 (6): 1143-1149. 10.1007/s00705-012-1584-4.CrossRefPubMedPubMedCentral Halfon P, Lindemann ML, Raimondo A, Ravet S, Camus C, Khiri H, Penaranda G, Sideri M, Sandri MT: HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test. Arch Virol. 2013, 158 (6): 1143-1149. 10.1007/s00705-012-1584-4.CrossRefPubMedPubMedCentral
18.
go back to reference Qiagen: LiquiChip applications handbook: for protein-based suspension arrays using xMAP technology. 2006, Qiagen Qiagen: LiquiChip applications handbook: for protein-based suspension arrays using xMAP technology. 2006, Qiagen
19.
go back to reference Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33 (1): 159-174. 10.2307/2529310.CrossRefPubMed Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33 (1): 159-174. 10.2307/2529310.CrossRefPubMed
20.
go back to reference Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ: Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol. 2006, 44 (10): 3680-3685. 10.1128/JCM.02078-05.CrossRefPubMedPubMedCentral Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ: Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol. 2006, 44 (10): 3680-3685. 10.1128/JCM.02078-05.CrossRefPubMedPubMedCentral
21.
go back to reference Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, Gonzalez P, Bratti MC, et al: Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste. Costa Rica. J Clin Microbiol. 2007, 45 (5): 1447-1454. 10.1128/JCM.02580-06.CrossRefPubMed Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, Gonzalez P, Bratti MC, et al: Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste. Costa Rica. J Clin Microbiol. 2007, 45 (5): 1447-1454. 10.1128/JCM.02580-06.CrossRefPubMed
22.
go back to reference Sandri MT, Lentati P, Benini E, Dell’Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, et al: Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol. 2006, 44 (6): 2141-2146. 10.1128/JCM.00049-06.CrossRefPubMedPubMedCentral Sandri MT, Lentati P, Benini E, Dell’Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, et al: Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol. 2006, 44 (6): 2141-2146. 10.1128/JCM.00049-06.CrossRefPubMedPubMedCentral
23.
go back to reference Stevens MP, Garland SM, Tabrizi SN: Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods. 2008, 147 (2): 290-296. 10.1016/j.jviromet.2007.09.018.CrossRefPubMed Stevens MP, Garland SM, Tabrizi SN: Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods. 2008, 147 (2): 290-296. 10.1016/j.jviromet.2007.09.018.CrossRefPubMed
Metadata
Title
Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays
Authors
Philippe Halfon
Maria Teresa Sandri
Audrey Raimondo
Sophie Ravet
Hacène Khiri
Mario Sideri
Guillaume Penaranda
Claire Camus
Maria Luisa Mateos Lindemann
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-499

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.